133 related articles for article (PubMed ID: 32314344)
1. Infliximab drug survival in chronic plaque psoriasis: follow-up of the product familiarisation program.
Berry W; Daniel B; Nguyen R; Baker C; Foley P
Australas J Dermatol; 2020 Nov; 61(4):e472-e474. PubMed ID: 32314344
[No Abstract] [Full Text] [Related]
2. Five-year experience with infliximab: Follow up of the product familiarisation program.
Nguyen R; Braue A; Baker C; Foley P
Australas J Dermatol; 2016 Nov; 57(4):300-306. PubMed ID: 26374405
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of juvenile generalized pustular psoriasis with infliximab therapy: two case reports.
Lu J; Li Y; Yu N; Chen F; Ding Y; Yi X
J Int Med Res; 2020 Mar; 48(3):300060520912091. PubMed ID: 32216562
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of infliximab in psoriatic patients over the age of 65.
Chiricozzi A; Pavlidis A; Dattola A; Bianchi L; Chimenti MS; Fida M; Saraceno R
Expert Opin Drug Saf; 2016 Nov; 15(11):1459-1462. PubMed ID: 27534970
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade)].
Valdés A Mdel P; Schroeder H F; Roizen G V; Honeyman M J; Sánchez M L
Rev Med Chil; 2006 Mar; 134(3):326-31. PubMed ID: 16676105
[TBL] [Abstract][Full Text] [Related]
7. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.
Torii H; Terui T; Matsukawa M; Takesaki K; Ohtsuki M; Nakagawa H;
J Dermatol; 2016 Jul; 43(7):767-78. PubMed ID: 26704926
[TBL] [Abstract][Full Text] [Related]
8. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis.
Tsang V; Dvorakova V; Enright F; Murphy M; Gleeson C
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e117-e119. PubMed ID: 26403378
[No Abstract] [Full Text] [Related]
9. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.
Wang J; Zhan Q; Zhang L
Hum Vaccin Immunother; 2016; 12(2):431-7. PubMed ID: 26528924
[TBL] [Abstract][Full Text] [Related]
10. First experience with therapy of severe forms of psoriasis with biosimilar infliximab.
Tichy M; Kopova R; Sternbersky J
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):491-3. PubMed ID: 25418715
[No Abstract] [Full Text] [Related]
11. Fast-growing 'giant' clear cell acanthoma detected by dermoscopy during treatment with infliximab in a psoriatic patient.
Cavicchini S; Nazzaro G; Marchetti S
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1642-4. PubMed ID: 24750337
[No Abstract] [Full Text] [Related]
12. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
13. Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry.
Gisondi P; Bianchi L; Conti A; Dapavo P; Malagoli P; Piaserico S; Savoia F; Prignano F; Girolomoni G
Br J Dermatol; 2017 Dec; 177(6):e325-e326. PubMed ID: 28498543
[No Abstract] [Full Text] [Related]
14. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
[No Abstract] [Full Text] [Related]
15. Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions.
Spertino J; Lopez-Ferrer A; Vilarrasa E; Puig L
J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1514-21. PubMed ID: 25493314
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
[TBL] [Abstract][Full Text] [Related]
17. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Yiu ZZN; Ashcroft DM; Evans I; McElhone K; Lunt M; Smith CH; Walton S; Murphy R; Reynolds NJ; Ormerod AD; Griffiths CEM; Warren RB;
Br J Dermatol; 2019 Feb; 180(2):329-337. PubMed ID: 30070708
[TBL] [Abstract][Full Text] [Related]
18. Exacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
Suh HY; Ahn JY; Park MY; Youn JI
J Dermatol; 2018 Mar; 45(3):332-333. PubMed ID: 28295521
[No Abstract] [Full Text] [Related]
19. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
Kamili QU; Miner A; Hapa A; Menter A
J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
